Pharmacogenetic dosing of warfarin in the Han-Chinese population: A randomized trial

Ming Shien Wen, Kuan Cheng Chang, Tsong Hai Lee, Ying Fu Chen, Kuo Chun Hung, Yeu Jhy Chang, Chia Wei Liou, Jin Jer Chen, Chien Hung Chang, Chao Yung Wang, Jiann Shing Jeng, Hui Ping Chuang, Ying Ting Chen, Chien Hsiun Chen, Jer Yuarn Wu, Yuan Tsong Chen, Ming Ta Michael Lee*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

38 Scopus citations

Abstract

Aim: This study aimed to determine clinical utility of genotype-guided dosing for warfarin in Han-Chinese. Methods: A total of 320 patients were randomly assigned International Warfarin Pharmacogenetic Consortium algorithm, Taiwan algorithm and optimal clinical care arms. The primary outcome of the study was the percentage of time in the therapeutic range during the first 90 days of treatment. Results: The percentage of time in the therapeutic range of the clinical care group in the first 2 weeks was significantly higher than the algorithm groups. This difference was no longer observed after 4 weeks. No difference in excessive anticoagulation (international normalized ratio ≥4.0) and adverse events was observed. Conclusion: Genotype-guided dosing did not provide significant benefit. Loading dose with frequent international normalized ratio monitoring could provide sufficient control of anticoagulation.

Original languageEnglish
Pages (from-to)245-253
Number of pages9
JournalPharmacogenomics
Volume18
Issue number3
DOIs
StatePublished - 02 2017

Bibliographical note

Publisher Copyright:
© 2017 Future Medicine Ltd.

Keywords

  • CYP2C9
  • VKORC1
  • dosing algorithms
  • pharmacogenetics
  • randomized trial
  • warfarin

Fingerprint

Dive into the research topics of 'Pharmacogenetic dosing of warfarin in the Han-Chinese population: A randomized trial'. Together they form a unique fingerprint.

Cite this